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Abstract: The development and extent of quinolone-resistance in broiler isolates of campylobacters over a 15-year period was
investigated. Minimal inhibitory concentrations of enrofloxacin, ciprofloxacin and nalidixic acid for 567 Campylobacter jejuni and 233
Campylobacter coli strains were determined by the agar dilution method. Of the strains, 180, 420 and 200 were isolated during
1987, 1992 and 2000, respectively. Enrofloxacin or ciprofloxacin resistance was not found in isolates from 1987. The first
fluoroquinolone resistance (1.4% to enrofloxacin and 1.2% to ciprofloxacin) appeared in strains isolated in 1992, approximately 2
years after the licensing of enrofloxacin in Turkey. The rate of resistance to nalidixic acid was 5.5% in 1987 and 7.3% in 1992.
However, the resistance of campylobacters to quinolones increased dramatically in 2000, with 75.5%, 73% and 94.5% of the
strains being resistant to enrofloxacin, ciprofloxacin and nalidixic acid, respectively. Fluoroquinolone resistant strains originated from
7.1% of 28 broiler flocks in 1992, and from 92.9% of 14 flocks in 2000. In total, 18% of C. jejuni and 24% of C. coli strains
were resistant to enrofloxacin, and 17.5% of C. jejuni and 22.3% of C. coli strains were resistant to ciprofloxacin. A high level of
cross-resistance was observed among enrofloxacin, ciprofloxacin and nalidixic acid. It was concluded that the uncontrolled use of
fluoroquinolones in animals in Turkey caused the emergence and spread of high level resistance among poultry strains of
campylobacters, which may have serious effects on both animal and human health and may be a serious food safety concern.
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Türkiye’de Tavuk Kökenli Campylobacter Sufllar›nda Quinolone Dirençlili¤inin Yükselifli
Özet: Onbefl y›ll›k bir periyotta, broiler kökenli Campylobacter sufllar›nda quinolone dirençlili¤inin geliflimi ve boyutlar› incelendi.
Çal›flmada, enrofloxacin, ciprofloxacin ve nalidixic asitin 180’i 1987, 420’si 1992 ve 200’ü 2000 y›llar›na ait olan 567 C. jejuni ve
233 C. coli izolat› için MIC de¤erleri agar dilüsyon yöntemiyle saptand›. 1987 y›l› izolatlar›nda enrofloxacin veya ciprofloxacin
dirençlili¤i bulunmad›. ‹lk fluoroquinolone dirençlili¤i (enrofloxacine % 1,4 ve ciprofloxacine % 1,2) enrofloxacin’in Türkiye’de lisans
ald›¤› 1989 y›l›ndan yaklafl›k iki y›l sonra, 1992’de izole edilen sufllarda görüldü. Nalidixic asite karfl› 1987’de % 5,5 ve 1992’de %
7,3 oran›nda direnç saptand›. Ancak, 2000 y›l› Campylobacter sufllar›nda, enrofloxacin, ciprofloxacin ve nalidixic asite karfl› s›ras›yla
% 75,5, 73 ve 94,5 oranlar› ile, quinolone dirençlili¤i dramatik bir art›fl gösterdi. Fluoroquinolone dirençli sufllar 1992’de 28 broiler
iflletmesinin % 7,1’inde, 2000’de 14 iflletmenin % 92,9’unda belirlendi. Toplamda, C. jejuni sufllar›n›n % 18’i ve C. coli sufllar›n›n %
24’ü enrofloxacine, C. jejuni sufllar›n›n % 17,5’i ve C. coli sufllar›n›n % 22,3’ü ciprofloxacine dirençli bulundu. Enrofloxacin,
ciprofloxacin ve nalidixic asit aras›nda yüksek düzeyde çapraz dirençlilik görüldü. Türkiye’de hayvanlarda kontrolsüz fluoroquinolone
kullan›m›n›n, kanatl› Campylobacter sufllar›nda yüksek düzeyde direnç oluflumuna ve yay›l›m›na yol açt›¤›, bunun da g›da güvenli¤i,
befleri ve veteriner hekimlik aç›s›ndan olas›l›kla ciddi sonuçlar do¤uraca¤› sonucuna var›ld›.
Anahtar Sözcükler: Campylobacter, quinolone, direnç, tavuk

Introduction
Thermophilic
campylobacters,
Campylobacter jejuni and Campylobacter
intestinal commensals of domesticated birds.
doses of thermophilic Campylobacter cells are

including
coli are
Very low
sufficient

to colonize chicks, and campylobacters generally enter
into a non-pathologic, commensal association within the
intestine following colonization (1,2). Previous studies on
Campylobacter carriage of commercial broilers have
reported prevalence rates of 81-100% (3,4). The
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significance of Campylobacter carriage of poultry relates
to the potential infection of consumers, and poultry is
established as a significant risk factor in the transmission
of campylobacters to humans (5). In consequence, the
most frequently identified cause of acute diarrheal
infection in humans is now thermophilic campylobacters
in many parts of the world.
Quinolones are antibacterial agents that act by
inhibiting DNA gyrase and topoisomerase IV in susceptible
bacteria (6). In addition to the original non-fluorinated
quinolone class, there are more than a dozen
fluoroquinolones that are approved for use throughout
the world. Fluoroquinolones have been widely used in
almost all kinds of infection in human and veterinary
medicine because of their wide spectra and high levels of
antimicrobial activity (7). They have also been used for
the treatment of Campylobacter infections and for the
empiric treatment of gastroenteritis (8,9). Despite initial
optimism, resistance to fluoroquinolone antibiotics
among bacteria has increased significantly since their
introduction into medicine and agriculture in the late
1980s. Microbial resistance to fluoroquinolones results
from mutations in topoisomerase II (DNA gyrase),
topoisomerase IV, and/or the activation of drug efflux
pumps (6). In Gram-negative organisms, resistance to
fluoroquinolones has been shown to be most frequently
associated with alterations in gyrA, but high-level
resistance involves the acquisition of mutations at
multiple loci (6). However, C. jejuni and C. coli tend to
develop resistance to quinolones because, unlike in many
other species, a single point mutation in the quinolone
resistance determining region of their gyrA genes suffices
to confer high-level resistance (8-11). As a consequence
of the widespread use of quinolones in both humans and
food animals, the prevalence of quinolone resistant
Campylobacter has increased markedly in many parts of
the world in the last decade, with the highest occurrences
of 97% in human isolates (12-14) and 99% in broiler
isolates (4,15). In Turkey, fluoroquinolones were
introduced into veterinary practice in 1989, and no
resistance was determined in broiler isolates of
campylobacters in 1987 and 1992 (16). The aim of this
study was to determine the presence and extent of
fluoroquinolone resistance in broiler isolates of
campylobacters, since no reports were available on this
subject in the last decade in Turkey.
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Materials and Methods
Campylobacter strains and culture conditions: All
Campylobacter strains were consecutive isolates collected
from broilers at the Department of Microbiology, Faculty
of Veterinary Medicine, Ankara University, in 1987, 1992
and 2000. Strains of the 1987, 1992 and 2000 periods
were isolated from 11, 28 and 14 different flocks,
respectively. For the isolation of campylobacters, rectal
and carcass samples collected from broilers were directly
plated on Skirrow or Preston selective agar plates (Oxoid)
and incubated at 37 °C in a microaerobic atmosphere for
48 h. Identification of suspected colonies was performed
by conventional biochemical and tolerance tests (17).
Campylobacters were stored frozen at –80 °C in glycerolBrucella broth (Oxoid), and only one strain per sample
was kept for further study. In the study, 180 isolates
from 1987, 420 isolates from 1992 and 200 isolates
from 2000 were used. In the susceptibility test, 567 C.
jejuni and 233 C. coli strains were included. Distribution
of C. jejuni and C. coli strains by year was as follows: 113
and 67 in 1987, 318 and 102 in 1992, and 136 and 64
in 2000.
Antimicrobial susceptibility tests: The MICs of nalidixic
acid (Sigma), ciprofloxacin and enrofloxacin (Bayer) for
campylobacters were determined by the agar doubling
dilution method. Briefly, the strains grown overnight on
Columbia agar (Oxoid) containing 5% sheep blood were
suspended in sterile saline and adjusted to a turbidity
matching a 0.5 McFarland standard. An inoculum of 2 µl
containing 105 CFU was plated in a single spot on a series
of Mueller-Hinton agar (Oxoid) containing two-fold serial
dilutions of nalidixic acid, ciprofloxacin or enrofloxacin.
The range of antibiotic concentrations tested was 0.03
µg/ml to 256 µg/ml for nalidixic acid, and 0.03 µg/ml to
128 µg/ml for ciprofloxacin and enrofloxacin. The
inoculated plates were incubated at 37 °C for 48 h in a
microaerobic atmosphere containing 5% O2, 10% CO2
and 85% H2. The MIC was defined as the lowest
concentration of the drug that completely inhibited visible
growth after incubation. The interpretive breakpoints for
the MICs to nalidixic acid were ≤8 µg/ml as susceptible
and ≥32 µg/ml as resistant. The interpretive breakpoints
for the MICs to ciprofloxacin were ≤1 µg/ml as
susceptible and ≥4 µg/ml as resistant (18). For
enrofloxacin, Bayer’s recommendations were ≤0.5 µg/ml
as susceptible and ≥2 µg/ml as resistant. MICs at which
50% and 90% of isolates were inhibited were also
determined as MIC50 and MIC90 values, respectively.
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Results
In this study, a total of 800 campylobacters
comprising 567 C. jejuni and 233 C. coli strains were
used. Of the strains used 180, 420 and 200 were isolated
during 1987, 1992 and 2000, respectively. Overall
results of antimicrobial susceptibility tests represented as
MIC values of enrofloxacin, ciprofloxacin and nalidixic acid
for campylobacters in the 3 different periods are shown
in Table 1. In 1987, none of the 180 isolates was
resistant to enrofloxacin or ciprofloxacin, as shown in
Figure 1. The prevalence of nalidixic acid resistance
among Campylobacter strains was also low (5.5%) in
that year. In 1992, resistance to enrofloxacin,
ciprofloxacin and nalidixic acid was found in 1.4%, 1.2%
and 7.3% of the 420 Campylobacter strains tested,
respectively. In 2000, the resistance of campylobacters to
quinolones increased significantly, with 75.5%, 73% and
94.5% of strains being resistant to enrofloxacin,

ciprofloxacin and nalidixic acid, respectively. In this
period, for both enrofloxacin and ciprofloxacin, MIC
ranges were between 0.25 µg/ml and 128 µg/ml, and the
MIC90 values were 32 µg/ml. MIC ranges of nalidixic acid
were between 64 µg/ml and ≥256 µg/ml, and the MIC90
value was ≥256 µg/ml. Fluoroquinolone-resistant strains
originated from 2 (7.1%) of 28 flocks in 1992, and 13
(92.9%) of 14 flocks in 2000.
In all instances, the prevalence of resistance to
quinolones was slightly higher in C. coli strains than in C.
jejuni strains (Table 2). In total, 18% of 567 C. jejuni and
24% of 233 C. coli were resistant to enrofloxacin, and
17.5% of C. jejuni and 22.3% of C. coli strains were
resistant to ciprofloxacin. A high level of cross-resistance
was observed among enrofloxacin, ciprofloxacin and
nalidixic acid when the MIC values of fluoroquinolones
were compared with nalidixic acid for 800 Campylobacter
strains (Figures 2a and 2b). None of the nalidixic acid

Table 1. Frequency distributions of quinolone MICs for Campylobacter isolates obtained in 1987, 1992 and 2000.
Percentage of isolates for which the MIC (µg/ml) was:
0.06

0.12

0.25

0.5

1

2

4

8

16

32

64

128

≥256

Enrofloxacin
Ciprofloxacin
Nalidixicacid

7.8
4.4
-

13.9
11.7
-

36.7
9.4
-

31.1
37.8
2.8

6.6
8.9
4.4

3.9
5.0
11.1

2.8
23.9

25.6

16.1

10.0

4.4

1.7

-

-

1992
(n: 420)

Enrofloxacin
Ciprofloxacin
Nalidixicacid

6.7
1.2
-

11.2
2.8
-

31.4
28.3
-

37.9
39.8
3.3

7.1
18.1
6.5

4.3
5.5
14.8

1.4
3.1
17.1

1.2
25.2

16.9

8.8

4.0

2.1

1.2

-

2000
(n: 200)

Enrofloxacin
Ciprofloxacin
Nalidixicacid

-

-

-

4.5
2.0
-

8.0
4.5
-

11.5
9.0
-

22.5
11.5
-

28.0
21.0
-

13.0
26.5
-

6.5
15.0
5.5

3.5
7.0
20.0

1.5
2.5
32.5

1.0
1.0
24.5

17.5

Quinolone

1987
(n: 180)

Resistance Percentage

≤0.03

Year

100
90
80
70
60
50
40
30
20
10
0

94.5
75.5 73

0

0
1987

5.5

1.4

1.2

1992
Years
en cip

7.3
2000
na

Figure 1. Emergence of quinolone resistance among broiler isolates of
campylobacters in Turkey. One hundred and eighty isolates were
collected in 1987, 420 isolates in 1992, and 200 isolates in 2000.
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Comparison of quinolone resistance in C. jejuni and C. coli
isolates. The numbers within the table indicate “number of
resistant/number of tested (percentage)”.

16

100

8

91

4

6 109

2

53 28

1

13

0.5

394

64

128

6

2
4
50

5

2

37

12

37

29

5

76

≥256

25 24

128

28

64
32

49 13

16

50

8

6 146

2

16

66

1

8

24

0.5

10

9
64

b

128

4

2

1

0.5

0.25

0.25
0.12

0.06

NA

4

39

3

0.03

Introduction of the fluoroquinolones in the late 1980s
provided clinicians with a class of broad-spectrum agents
applicable to a range of infections including urinary tract,
gastrointestinal, respiratory tract, bone and joint
infections, sexually transmitted diseases and infections of
the skin and soft tissue (7). The World Health
Organization has estimated the annual use of quinolones
to be about 120 metric tons, mainly in the United States,
the European Union and Japan, and 1.820 tons in China
alone (19). During 1997, the use of fluoroquinolones
within the European Union has been estimated at 43
tons. The clinical use of fluoroquinolones continues to
increase, and they now account for roughly 11% of
antimicrobial prescriptions worldwide (20). While
information on global use is limited, worldwide use in
food animals has been estimated at 120 tons in 1997
(21). In Turkey, the fluoroquinolone enrofloxacin was
first licensed for use in veterinary medicine in March
1989, and ciprofloxacin was approved 1 year later for
use in human clinical practice. The multiple clinical
indications for ciprofloxacin and enrofloxacin, in
particular, have led to extensive use of these compounds
in many parts of the world, including Turkey, for over a
decade. However, widespread use of this class of agents
has resulted in an increasing incidence of fluoroquinolone

14

enrofloxacin (µg/ml)

Nalidixic acid (µg/ml)

Discussion

32

0.25

5

susceptible strains showed resistance to enrofloxacin and
ciprofloxacin. All ciprofloxacin resistant strains were also
resistant to enrofloxacin.

NA

a

19
16

5/67 (7.5)
11/102 (10.8)
62/64 (96.9)

≥256

32

33

32

6/113 (5.3)
20/318 (6.3)
127/136 (93.4)

2

128

16

1987
1992
2000

22

3

64

8

0/67 (0.0)
2/102 (2.0)
50/64 (78.1)

7

3

4

0/113 (0.0)
3/318 (0.9)
96/136 (70.6)

1

23

13

16

8

1987
1992
2000

61

11 43

2

0/67 (0.0)
2/102 (2.0)
54/64 (84.4)

33

1

0/113 (0.0)
4/318 (1.3)
98/136 (72.1)

33

5

37

0.5

C. coli

0.25

Nalidixic acid

C. jejuni

25

0.12

Ciprofloxacin

1987
1992
2000

Resistance (%)

0.06

Enrofloxacin

Year

0.03

Quinolone

10

Nalidixic acid (µg/ml)

Table 2.

ciprofloxacin (µg/ml)

Figure 2. Scattergrams for 800 Campylobacter isolates correlating
the MICs of nalidixic acid to those of enrofloxacin (a), and
ciprofloxacin (b). The numbers within the dashed boxes
indicate the numbers of Campylobacter isolates.

resistance in many bacteria all over the world (20). The
development of clinically significant levels of resistance in
animal strains of campylobacters would cause serious
problems in human and veterinary medicine, since
campylobacteriosis is considered a zoonotic disease, and
animals such as poultry may act as reservoirs for
campylobacters. In this regard, it was of great
importance to ascertain the prevalence of quinolone
resistant campylobacters of avian origin in Turkey.
In this study, all Campylobacter isolates collected in
1987 were susceptible to fluoroquinolones, and most
strains were susceptible to nalidixic acid. This was a
predictable finding, since fluoroquinolones were not in

S. SAVAfiAN, A. Ç‹FTÇ‹, K. S. D‹KER

use in 1987, and nalidixic acid was not a veterinary drug.
In other studies conducted prior to the introduction of
fluoroquinolones into practice, resistance has not been
observed in human or animal isolates of campylobacters
in Turkey (16,22). However, the first fluoroquinolone
resistant strains (1.4% to enrofloxacin and 1.2% to
ciprofloxacin) appeared in 1992, approximately 2 years
after the licensing of fluoroquinolones. It was the
occurrence of resistance only 2 years after the limited use
of fluoroquinolones, that raised the alarm. The first cases
of fluoroquinolone resistance with similar rates to those
in the current study have been also reported generally in
this period from all around the world, particularly in
European countries (23,24). The rate of resistance to
enrofloxacin rose dramatically from 1.4% in 1992 to
75.5% in 2000 in the present study. To our knowledge,
this is one of the highest prevalences of resistance to
fluoroquinolones in campylobacters that has been
reported in recent years. Similar patterns of resistance
development have also been noted in other studies.
Ciprofloxacin resistance has been found in 99% of broiler
isolates of campylobacters in Spain (4) and 62.1% in
Belgium (15). In human isolates, high resistance rates
have been reported in Spain (81%)(13), Hong Kong
(97%) (14) and Thailand (84%) (12). Among these high
resistance rates, it is also possible to see low level
resistance to fluoroquinolones (as low as 10%) in
occasional studies. These contradictory findings may be
caused by prohibited use or later licensing of these drugs
in some countries. In this study, we encountered a higher
prevalence of resistance to quinolones in C. coli than in C.
jejuni. Prats et al. (13) and Aquino et al. (25) have also
reported that C. coli is more resistant to quinolones than
is C. jejuni.
Development of resistance to nonfluorinated (nalidixic
acid) and fluorinated (enrofloxacin and ciprofloxacin)
quinolones followed the same patterns in all the years
considered in the study (Figure 2). The similar
proportions and speeds of resistance showed that cross
resistance had occurred between nalidixic acid and
fluoroquinolones. The level of resistance to enrofloxacin
(used in domestic animals) was also the same as the level
of resistance to ciprofloxacin (available for human clinical
use). This is due to the fact that resistance to one
fluoroquinolone generally confers this on the entire class
of fluoroquinolone drugs (10,13). This may be explained
by the fact that a single mutation in either topoisomerase

can confer resistance to both nonfluorinated and
fluorinated quinolones in C. jejuni or C. coli (8,9).
The high levels of quinolone resistance detected in
campylobacters in the present study may be caused by
several factors. C. jejuni and C. coli tend to develop
resistance to quinolones because, unlike in many other
species, a single point mutation in the quinolone
resistance-determining region (QRDR) of its gyrA gene
suffices to confer high-level resistance (8,9). This may
explain the significantly higher level of quinolone
resistance in Campylobacter when compared with other
genera. Exposure of a microorganism to a
fluoroquinolone has been shown to be the most
significant factor in the selection of resistant mutants.
The isolation of resistant mutants of campylobacters in
vivo after therapeutic treatment with quinolone has been
reported by several authors (26,27). Quinolone
treatment of Campylobacter-colonized broiler chickens
has been established to induce quinolone resistance under
experimental conditions within 5 days (28,29). In
Turkey, the addition of antimicrobial agents to feed or
water for therapeutic or prophylactic purposes remains
uncontrolled, and the volume of drugs used is high.
Intensively farmed animals are often treated as a group
and are given massive amounts of medication. In addition,
quinolones are mostly excreted as unchanged substances
and are among the most persistent drugs in the
environment (30). Therefore, the discharge of quinolones
in the environment may increase the risk of further
contact with environmental strains and select resistant
mutants among bacterial populations. Since
fluoroquinolones are in extensive use for all bacterial
infections in Turkey, conditions of high selective pressure
have forced the mutant Campylobacter strains to multiply
and establish themselves as the dominant population. The
abusive and anarchic use of antibiotics is probably the
leading factor in the high levels of resistance detected
among avian Campylobacter strains in Turkey.
Resistance to quinolones in campylobacters bears on
both diagnostic and therapeutic aspects. Nalidixic acid
resistance has been used as an important phenotypic
marker to distinguish between C. jejuni/C. coli and C.
fetus subsp. fetus or C. lari (17). C. jejuni/C. coli strains
have generally been regarded as susceptible to nalidixic
acid, whereas most C. fetus subsp. fetus and C. lari
strains are intrinsically resistant to high levels of nalidixic
acid. Thus, resistance to quinolones in campylobacters is
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regarded as an important tool for their identification.
However, increasing resistance (up to 94.5%) of C. jejuni
and C. coli strains to nalidixic acid as detected in this study
shows that nalidixic acid resistance should not be used as
a criterion in the differentiation of Campylobacter species
any more. The high prevalence of quinolone resistance
detected in broiler isolates of campylobacters may have
important consequences for public health. Human
Campylobacter infections usually occur following
ingestion of improperly handled or undercooked food,
and poultry meat has been considered as the most
common source of infection (5). Fluoroquinolones are
often recommended to patients who require treatment
(7). However, if a person is infected with quinolone
resistant campylobacters of poultry origin, this drug will

be ineffective. Before fluoroquinolones were introduced
into veterinary medicine, they had been widely used in
human medicine in a number of countries without the
emergence of quinolone resistance. In contrast, emerging
quinolone resistance in humans often coincides with or
follows the approval of the use of fluoroquinolones in
animal husbandry (11). In this study, it was concluded
that the use of fluoroquinolones in veterinary medicine
caused the emergence and spread of resistance among
Campylobacter strains, with potentially serious effects on
food safety and on both animal and human health. These
findings should reinforce the message that preventing the
spread of antibiotic resistance requires the prudent and
controlled use of antibiotics, not only in humans but also
in veterinary medicine.
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